Merck
Presença
Merck é uma das ...
- Forbes Global 2000 (#73);
- Fortune 500 (#69);
- Fortune 500 Europe (#165);
- Global Fortune 500 (#230);
- Russell 3000;
- S&P 500;
- Stoxx 600.
Merck é uma empresa listada sob o símbolo MRK (US).
Merck tem presença direta em 30 países.Merck possui 41 subsidiárias incluindo Merck Animal Health, Merck Cardiovascular e Merck Human Health.
Eles estão dentro:
- Farmacêutica83%
- Biotecnologia14%
- Outro2%
Fusão, aquisição e financiamento envolvendo Merck.
- Merck has announced the acquisition of Prometheus Biosciences (publicado em 19 de abril de 2023).
- Merck has announced the acquisition of Imago BioSciences (publicado em 11 de janeiro de 2023).
- Merck has announced the acquisition of Imago BioSciences (publicado em 23 de novembro de 2022).
- Merck has announced the acquisition of Seagen (publicado em 7 de julho de 2022).
- Veja mais notícias sobre a Merck Hide news involving Merck
Executivos
Veja o organograma con seus 258 executivos principais
Biografias mais buscadas da Merck
- Robert Davis, Chief Executive Officer and Chairman of the Board
- Mary Ellen Coe, Director
- Stephen Mayo, Director
Recentes movimentos de executivos em Merck
- Dalton Smart antes Vice President, Corporate Audit and Assurance Services, foi promovido a Senior Vice President, Finance and Global Controller (Notícia publicada em 5 de dezembro de 2023).
- Rita Karachun, Senior Vice President Finance, Global Controller and Principal Accounting Officer, se aposentou (Notícia publicada em 5 de dezembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Merck.
Farmacêutica
Merck possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Merck
- Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer - Merck.com
- REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer - Merck.com
- Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 - Merck.com
- Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer - Merck.com
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) - Merck.com
- European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults - Merck.
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer - Merck.com
- Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults - Merck.com
- Merck Completes Acquisition of Harpoon Therapeutics, Inc. - Merck.com
- Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9 - Merck.com
- View more press releases Close
Redes sociais sobre Merck
- Merck na Wikipedia, Google News e Yahoo Finance
- Merck na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Thomas Glocer 
Ligue para a Merck em +1 908...
